QQQ   283.62 (-1.40%)
AAPL   144.80 (-1.25%)
MSFT   246.79 (-1.36%)
META   115.58 (-5.60%)
GOOGL   97.23 (-2.26%)
AMZN   89.50 (-1.66%)
TSLA   179.47 (-1.63%)
NVDA   161.46 (-2.79%)
NIO   13.24 (+3.44%)
BABA   91.53 (+1.12%)
AMD   71.42 (-2.99%)
T   19.01 (+1.39%)
MU   54.49 (+0.83%)
CGC   3.76 (-12.96%)
F   13.24 (-1.05%)
GE   85.27 (+0.72%)
DIS   93.87 (-2.15%)
AMC   7.03 (-5.64%)
PYPL   72.67 (-1.29%)
PFE   49.83 (-1.77%)
NFLX   306.70 (-1.88%)
QQQ   283.62 (-1.40%)
AAPL   144.80 (-1.25%)
MSFT   246.79 (-1.36%)
META   115.58 (-5.60%)
GOOGL   97.23 (-2.26%)
AMZN   89.50 (-1.66%)
TSLA   179.47 (-1.63%)
NVDA   161.46 (-2.79%)
NIO   13.24 (+3.44%)
BABA   91.53 (+1.12%)
AMD   71.42 (-2.99%)
T   19.01 (+1.39%)
MU   54.49 (+0.83%)
CGC   3.76 (-12.96%)
F   13.24 (-1.05%)
GE   85.27 (+0.72%)
DIS   93.87 (-2.15%)
AMC   7.03 (-5.64%)
PYPL   72.67 (-1.29%)
PFE   49.83 (-1.77%)
NFLX   306.70 (-1.88%)
QQQ   283.62 (-1.40%)
AAPL   144.80 (-1.25%)
MSFT   246.79 (-1.36%)
META   115.58 (-5.60%)
GOOGL   97.23 (-2.26%)
AMZN   89.50 (-1.66%)
TSLA   179.47 (-1.63%)
NVDA   161.46 (-2.79%)
NIO   13.24 (+3.44%)
BABA   91.53 (+1.12%)
AMD   71.42 (-2.99%)
T   19.01 (+1.39%)
MU   54.49 (+0.83%)
CGC   3.76 (-12.96%)
F   13.24 (-1.05%)
GE   85.27 (+0.72%)
DIS   93.87 (-2.15%)
AMC   7.03 (-5.64%)
PYPL   72.67 (-1.29%)
PFE   49.83 (-1.77%)
NFLX   306.70 (-1.88%)
QQQ   283.62 (-1.40%)
AAPL   144.80 (-1.25%)
MSFT   246.79 (-1.36%)
META   115.58 (-5.60%)
GOOGL   97.23 (-2.26%)
AMZN   89.50 (-1.66%)
TSLA   179.47 (-1.63%)
NVDA   161.46 (-2.79%)
NIO   13.24 (+3.44%)
BABA   91.53 (+1.12%)
AMD   71.42 (-2.99%)
T   19.01 (+1.39%)
MU   54.49 (+0.83%)
CGC   3.76 (-12.96%)
F   13.24 (-1.05%)
GE   85.27 (+0.72%)
DIS   93.87 (-2.15%)
AMC   7.03 (-5.64%)
PYPL   72.67 (-1.29%)
PFE   49.83 (-1.77%)
NFLX   306.70 (-1.88%)
NASDAQ:VCNX

Vaccinex - VCNX Stock Forecast, Price & News

$0.75
+0.01 (+1.01%)
(As of 12/6/2022 11:46 AM ET)
Add
Compare
Today's Range
$0.71
$0.75
50-Day Range
$0.44
$0.74
52-Week Range
$0.41
$2.28
Volume
928 shs
Average Volume
56,848 shs
Market Capitalization
$31.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
VCNX stock logo

About Vaccinex (NASDAQ:VCNX) Stock

Vaccinex, Inc., a clinical-stage biotechnology company, focuses on treating cancer and neurodegenerative disease through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. It has also developed a proprietary drug discovery platform, ActivMAb that it is leveraging through strategic collaborations, by exploiting its unique capability to select antibodies against multi-pass membrane receptors. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.

Receive VCNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vaccinex and its competitors with MarketBeat's FREE daily newsletter.

VCNX Stock News Headlines

Vaccinex, Inc. (NASDAQ:VCNX) Short Interest Update
Vaccinex Announces $3.8 Million Private Placement
See More Headlines
Receive VCNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vaccinex and its competitors with MarketBeat's FREE daily newsletter.

VCNX Company Calendar

Last Earnings
11/08/2021
Today
12/06/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/30/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VCNX
Employees
39
Year Founded
N/A

Profitability

Net Income
$-22,380,000.00
Pretax Margin
-38,736.00%

Debt

Sales & Book Value

Annual Sales
$900,000.00
Book Value
$0.24 per share

Miscellaneous

Free Float
22,356,000
Market Cap
$31.87 million
Optionable
Not Optionable
Beta
1.23

Key Executives

  • Dr. Maurice Zauderer Ph.D.Dr. Maurice Zauderer Ph.D. (Age 76)
    Co-Founder, CEO, Pres & Director
    Comp: $374.9k
  • Mr. Scott E. Royer C.F.A. (Age 48)
    M.B.A., Chief Financial Officer
    Comp: $242.15k
  • Dr. Ernest S. Smith Ph.D. (Age 50)
    Sr. VP of Research & Chief Scientific Officer
    Comp: $264.74k
  • Dr. Elizabeth E. Evans Ph.D. (Age 49)
    COO and Sr. VP of Discovery & Translational Medicine
  • Dr. John E. Leonard Ph.D. (Age 75)
    Sr. VP of Devel.













VCNX Stock - Frequently Asked Questions

How have VCNX shares performed in 2022?

Vaccinex's stock was trading at $1.04 at the start of the year. Since then, VCNX stock has decreased by 28.9% and is now trading at $0.7395.
View the best growth stocks for 2022 here
.

Are investors shorting Vaccinex?

Vaccinex saw a drop in short interest during the month of November. As of November 15th, there was short interest totaling 129,900 shares, a drop of 50.9% from the October 31st total of 264,300 shares. Based on an average daily trading volume, of 71,900 shares, the days-to-cover ratio is currently 1.8 days. Currently, 0.6% of the company's shares are short sold.
View Vaccinex's Short Interest
.

When is Vaccinex's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023.
View our VCNX earnings forecast
.

How were Vaccinex's earnings last quarter?

Vaccinex, Inc. (NASDAQ:VCNX) announced its quarterly earnings data on Monday, November, 8th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.29) by $0.12. The firm earned $0.05 million during the quarter.

What other stocks do shareholders of Vaccinex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vaccinex investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Aldeyra Therapeutics (ALDX), Sorrento Therapeutics (SRNE), Cerecor (CERC), Exelixis (EXEL), Pfizer (PFE), AVEO Pharmaceuticals (AVEO), Heat Biologics (HTBX) and SCYNEXIS (SCYX).

When did Vaccinex IPO?

(VCNX) raised $45 million in an IPO on Thursday, August 9th 2018. The company issued 3,300,000 shares at $12.00-$15.00 per share. Oppenheimer and BTIG acted as the underwriters for the IPO and Ladenburg Thalmann was co-manager.

What is Vaccinex's stock symbol?

Vaccinex trades on the NASDAQ under the ticker symbol "VCNX."

Who are Vaccinex's major shareholders?

Vaccinex's stock is owned by a variety of institutional and retail investors. Top institutional investors include Citadel Advisors LLC (0.24%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Albert Friedberg, Jacob B Frieberg, Maurice Zauderer and Strydonck Gerald E Van.
View institutional ownership trends
.

How do I buy shares of Vaccinex?

Shares of VCNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vaccinex's stock price today?

One share of VCNX stock can currently be purchased for approximately $0.74.

How much money does Vaccinex make?

Vaccinex (NASDAQ:VCNX) has a market capitalization of $31.55 million and generates $900,000.00 in revenue each year. The company earns $-22,380,000.00 in net income (profit) each year or ($0.51) on an earnings per share basis.

How can I contact Vaccinex?

Vaccinex's mailing address is 1895 MOUNT HOPE AVENUE, ROCHESTER NY, 14620. The official website for the company is www.vaccinex.com. The company can be reached via phone at (585) 271-2700, via email at mrice@lifesciadvisors.com, or via fax at 585-271-2765.

This page (NASDAQ:VCNX) was last updated on 12/6/2022 by MarketBeat.com Staff